Cordis European Cypher Stent Launch Showing Mixed Initial Results
Johnson & Johnson says it has converted 6% of the European coronary stent market to its drug-eluting Cypher stent; however, sales have fallen short of preliminary expectations
Johnson & Johnson says it has converted 6% of the European coronary stent market to its drug-eluting Cypher stent; however, sales have fallen short of preliminary expectations